In the pharmaceutical context, the intranasal route, in addition to predominantly local drug application, is also of great interest for systemic application. The COVID-19 pandemic revealed once again the role of the nose as a portal of entry for pathogens. The nasal mucosa has shown to be not only the main portal of entry of the SARS-CoV-2 virus into the human body, but also an important site for replication of the virus. Within this context, the topic of the nasal mucosa as a site of entry for viruses, but also as a route of administration of systemic therapies and vaccines, is intensively discussed.
Read more about chances and challenges of intranasal applications for systemic drug delivery in our blog.